Sierra Oncology Inc (SRRA) PT Raised to $48 at Oppenheimer, Following Reverse SPlit

Oppenheimer analyst Jay Olson raised the price target on Sierra Oncology Inc (NASDAQ: SRRA) to $48.00 (from $1.20) while maintaining a Outperform rating.

Analyst comments: "We are encouraged by the favorable setup resulting from SRRA's reverse split of its common stock at a ratio of 1-for-40. While the reverse split was expected as to comply with NASDAQ listing requirements, we think current trading levels (above $12) may attract additional investors who would have previously been reluctant or restricted from investing in a stock trading below $1. We update our model with the reduced share count and adjust our PT to $48 while maintaining the same Outperform rating."

You May Also Be Interested In

• Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
• B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral
• Central Retail Corp PCL (CRC:TB) PT Lowered to THB9,000 at Macquarie